Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920485 | 1.00 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL18241088 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2862492 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4334091 | 0.93 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27821605 | 0.88 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2550326 | 0.86 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3401436 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL29676554 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3400330 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL6806463 | 0.84 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3910073-A1 | SPLICE VARIANTS ASSOCIATED WITH NEOMORPHIC SF3B1 MUTANTS | Eisai R&D Management Co., Ltd. (JP) | 2021-11-17 | — | — | EP | disclosed |
| EP-3344780-B1 | SPLICE VARIANTS ASSOCIATED WITH NEOMORPHIC SF3B1 MUTANTS | EISAI R&D MAN CO LTD (JP) | 2021-06-23 | — | — | EP | disclosed |
| CN-107074827-B | Pladienolide pyridine compounds and methods of use | 卫材研究发展管理有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3514154-A1 | PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| WO-2017040526-A2 | SPLICE VARIANTS ASSOCIATED WITH NEOMORPHIC SF3B1 MUTANTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-03-09 | — | — | WO | disclosed |
| EP-1976842-B1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH SPA (IT) | 2010-03-10 | — | — | EP | disclosed |
| US-20100016288-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A (IT) | 2010-01-21 | — | — | US | disclosed |
| EP-1976842-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007082731-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | L3MBTL3 1258/4885L3MBTL1 1211/4885MBTD1 2432/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | L3MBTL3 1466/4885L3MBTL1 1259/4885MBTD1 2392/4885 |
| US-20100016288-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA6, CHRNA5 | L3MBTL3 3198/4885L3MBTL1 3135/4885MBTD1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.